Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Association of a homozygous GCK missense mutation with mild diabetes.

Marucci A, Biagini T, Di Paola R, Menzaghi C, Fini G, Castellana S, Cardinale GM, Mazza T, Trischitta V.

Mol Genet Genomic Med. 2019 Jul;7(7):e00728. doi: 10.1002/mgg3.728. Epub 2019 Jun 14.

2.

Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE): An Inexpensive and Parsimonious Prediction Model.

Copetti M, Shah H, Fontana A, Scarale MG, Menzaghi C, De Cosmo S, Garofolo M, Sorrentino MR, Lamacchia O, Penno G, Doria A, Trischitta V.

J Clin Endocrinol Metab. 2019 Oct 1;104(10):4900-4908. doi: 10.1210/jc.2019-00215.

PMID:
31087060
3.

Circulating adiponectin levels are paradoxically associated with mortality rate. A systematic review and meta-analysis.

Scarale MG, Fontana A, Trischitta V, Copetti M, Menzaghi C.

J Clin Endocrinol Metab. 2018 Nov 1. doi: 10.1210/jc.2018-01501. [Epub ahead of print]

PMID:
30388239
4.

Erratum. The Adiponectin Paradox for All-Cause and Cardiovascular Mortality. Diabetes 2018;67:12-22.

Menzaghi C, Trischitta V.

Diabetes. 2018 Dec;67(12):2710. doi: 10.2337/db18-er12a. Epub 2018 Oct 10. No abstract available.

5.

Can HbA1c combined with fasting plasma glucose help to assess priority for GCK-MODY vs HNF1A-MODY genetic testing?

Delvecchio M, Salzano G, Bonura C, Cauvin V, Cherubini V, d'Annunzio G, Franzese A, Giglio S, Grasso V, Graziani V, Iafusco D, Iughetti L, Lera R, Maffeis C, Maltoni G, Mantovani V, Menzaghi C, Patera PI, Rabbone I, Reindstadler P, Scelfo S, Tinto N, Toni S, Tumini S, Lombardo F, Nicolucci A, Barbetti F; Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetes (ISPED).

Acta Diabetol. 2018 Sep;55(9):981-983. doi: 10.1007/s00592-018-1179-y. Epub 2018 Jun 13. No abstract available.

PMID:
29948406
6.

The Adiponectin Paradox for All-Cause and Cardiovascular Mortality.

Menzaghi C, Trischitta V.

Diabetes. 2018 Jan;67(1):12-22. doi: 10.2337/dbi17-0016. Erratum in: Diabetes. 2018 Dec;67(12):2710.

7.
8.

Suggestive evidence of a multi-cytokine resistin pathway in humans and its role on cardiovascular events in high-risk individuals.

Menzaghi C, Marucci A, Antonucci A, De Bonis C, Ortega Moreno L, Salvemini L, Copetti M, Trischitta V, Di Paola R.

Sci Rep. 2017 Mar 14;7:44337. doi: 10.1038/srep44337.

9.

Serum resistin is causally related to mortality risk in patients with type 2 diabetes: preliminary evidences from genetic data.

Fontana A, Ortega Moreno L, Lamacchia O, De Bonis C, Salvemini L, De Cosmo S, Cignarelli M, Copetti M, Trischitta V, Menzaghi C.

Sci Rep. 2017 Mar 3;7(1):61. doi: 10.1038/s41598-017-00138-3.

10.

The combined effect of adiponectin and resistin on all-cause mortality in patients with type 2 diabetes: Evidence of synergism with abdominal adiposity.

Ortega Moreno L, Lamacchia O, Fontana A, Copetti M, Salvemini L, De Bonis C, Cignarelli M, Trischitta V, Menzaghi C.

Atherosclerosis. 2016 Jul;250:23-9. doi: 10.1016/j.atherosclerosis.2016.04.028. Epub 2016 Apr 27.

PMID:
27175608
11.

Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes.

Ortega Moreno L, Copetti M, Fontana A, De Bonis C, Salvemini L, Trischitta V, Menzaghi C.

Cardiovasc Diabetol. 2016 Jan 27;15:17. doi: 10.1186/s12933-016-0339-z.

12.

The paradoxical association of adiponectin with mortality rate in patients with type 2 diabetes: evidence of synergism with kidney function.

Ortega Moreno L, Lamacchia O, Salvemini L, De Bonis C, De Cosmo S, Cignarelli M, Trischitta V, Menzaghi C.

Atherosclerosis. 2016 Feb;245:222-7. doi: 10.1016/j.atherosclerosis.2015.12.026. Epub 2015 Dec 22.

PMID:
26735588
13.

Serum Adiponectin and Glomerular Filtration Rate in Patients with Type 2 Diabetes.

Ortega Moreno L, Lamacchia O, Copetti M, Salvemini L, De Bonis C, De Cosmo S, Cignarelli M, Trischitta V, Menzaghi C.

PLoS One. 2015 Oct 14;10(10):e0140631. doi: 10.1371/journal.pone.0140631. eCollection 2015.

14.

Strong evidence of sexual dimorphic effect of adiposity excess on insulin sensitivity.

Marucci A, Menzaghi C, Copetti M, Vinciguerra F, Baratta R, Salvemini L, Morini E, Frittitta L, Di Paola R, Trischitta V.

Acta Diabetol. 2015 Oct;52(5):991-8. doi: 10.1007/s00592-015-0804-2. Epub 2015 Aug 25.

PMID:
26302880
15.

Serum resistin and glomerular filtration rate in patients with type 2 diabetes.

Moreno LO, Salvemini L, Mendonca C, Copetti M, De Bonis C, De Cosmo S, Doria A, Trischitta V, Menzaghi C.

PLoS One. 2015 Mar 26;10(3):e0119529. doi: 10.1371/journal.pone.0119529. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0127250.

16.

Association between resistin levels and all-cause and cardiovascular mortality: a new study and a systematic review and meta-analysis.

Fontana A, Spadaro S, Copetti M, Spoto B, Salvemini L, Pizzini P, Frittitta L, Mallamaci F, Pellegrini F, Trischitta V, Menzaghi C.

PLoS One. 2015 Mar 20;10(3):e0120419. doi: 10.1371/journal.pone.0120419. eCollection 2015. Review.

17.

Joint effect of insulin signaling genes on all-cause mortality.

Menzaghi C, Fontana A, Copetti M, Rizza S, Spoto B, Buranasupkajorn P, Tripepi G, Marucci A, Bailetti D, Hastings T, Testa A, Mendonca C, Mallamaci F, De Cosmo S, Bacci S, Federici M, Doria A, Zoccali C, Trischitta V.

Atherosclerosis. 2014 Dec;237(2):639-44. doi: 10.1016/j.atherosclerosis.2014.10.005. Epub 2014 Oct 24.

18.

Low prevalence of HNF1A mutations after molecular screening of multiple MODY genes in 58 Italian families recruited in the pediatric or adult diabetes clinic from a single Italian hospital.

Delvecchio M, Ludovico O, Menzaghi C, Di Paola R, Zelante L, Marucci A, Grasso V, Trischitta V, Carella M, Barbetti F, Gallo F, Coccioli MS, Zecchino C, Faienza MF, Cardinale G, Franzese A, Mozzillo E, Iafusco D, Zanfardino A.

Diabetes Care. 2014 Dec;37(12):e258-60. doi: 10.2337/dc14-1788. No abstract available.

PMID:
25414397
19.

Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism.

Menzaghi C, Xu M, Salvemini L, De Bonis C, Palladino G, Huang T, Copetti M, Zheng Y, Li Y, Fini G, Hu FB, Bacci S, Qi L, Trischitta V.

Cardiovasc Diabetol. 2014 Sep 10;13:130. doi: 10.1186/s12933-014-0130-y.

20.

Clinical heterogeneity of abnormal glucose homeostasis associated with the HNF4A R311H mutation.

Delvecchio M, Di Paola R, Mangiacotti D, Sacco M, Menzaghi C, Trischitta V.

Ital J Pediatr. 2014 Jun 19;40:58. doi: 10.1186/1824-7288-40-58. No abstract available.

21.

Role of obesity on all-cause mortality in whites with type 2 diabetes from Italy.

Di Paola R, Marucci A, Fontana A, Menzaghi C, Salvemini L, Copetti M, Pellegrini F, De Cosmo S, Trischitta V.

Acta Diabetol. 2013 Dec;50(6):971-6.

PMID:
23959063
22.

GALNT2 expression is reduced in patients with Type 2 diabetes: possible role of hyperglycemia.

Marucci A, di Mauro L, Menzaghi C, Prudente S, Mangiacotti D, Fini G, Lotti G, Trischitta V, Di Paola R.

PLoS One. 2013 Jul 22;8(7):e70159. doi: 10.1371/journal.pone.0070159. Print 2013.

23.

Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes.

Menzaghi C, Bacci S, Salvemini L, Mendonca C, Palladino G, Fontana A, De Bonis C, Marucci A, Goheen E, Prudente S, Morini E, Rizza S, Kanagaki A, Fini G, Mangiacotti D, Federici M, De Cosmo S, Pellegrini F, Doria A, Trischitta V.

PLoS One. 2013 Jun 3;8(6):e64729. doi: 10.1371/journal.pone.0064729. Print 2014.

24.

Development and validation of a predicting model of all-cause mortality in patients with type 2 diabetes.

De Cosmo S, Copetti M, Lamacchia O, Fontana A, Massa M, Morini E, Pacilli A, Fariello S, Palena A, Rauseo A, Viti R, Di Paola R, Menzaghi C, Cignarelli M, Pellegrini F, Trischitta V.

Diabetes Care. 2013 Sep;36(9):2830-5. doi: 10.2337/dc12-1906. Epub 2013 May 1.

25.

Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence.

De Cosmo S, Menzaghi C, Prudente S, Trischitta V.

Nephrol Dial Transplant. 2013 Jan;28(1):29-36. doi: 10.1093/ndt/gfs290. Epub 2012 Oct 9. Review.

PMID:
23048172
26.

Genome-wide association analysis identifies TYW3/CRYZ and NDST4 loci associated with circulating resistin levels.

Qi Q, Menzaghi C, Smith S, Liang L, de Rekeneire N, Garcia ME, Lohman KK, Miljkovic I, Strotmeyer ES, Cummings SR, Kanaya AM, Tylavsky FA, Satterfield S, Ding J, Rimm EB, Trischitta V, Hu FB, Liu Y, Qi L.

Hum Mol Genet. 2012 Nov 1;21(21):4774-80. doi: 10.1093/hmg/dds300. Epub 2012 Jul 26.

27.

Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals.

Menzaghi C, Salvemini L, Fini G, Thompson R, Mangiacotti D, Di Paola R, Morini E, Giorelli M, De Bonis C, De Cosmo S, Doria A, Trischitta V.

PLoS One. 2012;7(6):e38414. doi: 10.1371/journal.pone.0038414. Epub 2012 Jun 12.

28.

The SH2B1 obesity locus is associated with myocardial infarction in diabetic patients and with NO synthase activity in endothelial cells.

Prudente S, Morini E, Larmon J, Andreozzi F, Di Pietro N, Nigro A, Gervino EV, Mannino GC, Bacci S, Hauser TH, Bellacchio E, Formoso G, Pellegrini F, Proto V, Menzaghi C, Frittitta L, Pandolfi A, Sesti G, Doria A, Trischitta V.

Atherosclerosis. 2011 Dec;219(2):667-72. doi: 10.1016/j.atherosclerosis.2011.08.019. Epub 2011 Aug 19.

29.

Novel locus FER is associated with serum HMW adiponectin levels.

Qi L, Menzaghi C, Salvemini L, De Bonis C, Trischitta V, Hu FB.

Diabetes. 2011 Aug;60(8):2197-201. doi: 10.2337/db10-1645. Epub 2011 Jun 23.

30.

Relationship between ADIPOQ gene, circulating high molecular weight adiponectin and albuminuria in individuals with normal kidney function: evidence from a family-based study.

Menzaghi C, De Cosmo S, Copetti M, Salvemini L, De Bonis C, Mangiacotti D, Fini G, Pellegrini F, Trischitta V.

Diabetologia. 2011 Apr;54(4):812-8. doi: 10.1007/s00125-010-2037-9. Epub 2011 Jan 13.

PMID:
21229348
31.

Genetics of serum resistin: a paradigm of population-specific regulation?

Menzaghi C, Trischitta V.

Diabetologia. 2010 Feb;53(2):226-8. doi: 10.1007/s00125-009-1589-z. Epub 2009 Nov 1. No abstract available.

PMID:
19882136
32.

Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy: evidence from a family-based study.

Menzaghi C, Salvemini L, Paroni G, De Bonis C, Mangiacotti D, Fini G, Doria A, Di Paola R, Trischitta V.

J Intern Med. 2010 Mar;267(3):287-94. doi: 10.1111/j.1365-2796.2009.02141.x. Epub 2009 Jun 11.

33.

ENPP1 Q121 variant, increased pulse pressure and reduced insulin signaling, and nitric oxide synthase activity in endothelial cells.

Bacci S, Di Paola R, Menzaghi C, Di Fulvio P, Di Silvestre S, Pellegrini F, Baratta R, Marucci A, Mastroianno S, Fini G, Formoso G, Consoli A, Perticone F, Frittitta L, Pandolfi A, Trischitta V.

Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1678-83. doi: 10.1161/ATVBAHA.109.189191. Epub 2009 Aug 13.

PMID:
19679831
34.

The protein tyrosine phosphatase receptor type f (PTPRF) locus is associated with coronary artery disease in type 2 diabetes.

Menzaghi C, Paroni G, De Bonis C, Coco A, Vigna C, Miscio G, Lanna P, Tassi V, Bacci S, Trischitta V.

J Intern Med. 2008 Jun;263(6):653-4. doi: 10.1111/j.1365-2796.2008.01924.x. Epub 2008 Feb 20. No abstract available. Erratum in: J Intern Med. 2008 Aug;264(2):204.

35.

Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease.

Menzaghi C, Trischitta V, Doria A.

Diabetes. 2007 May;56(5):1198-209. Epub 2007 Feb 15. Review.

36.

Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians.

Menzaghi C, Coco A, Salvemini L, Thompson R, De Cosmo S, Doria A, Trischitta V.

J Clin Endocrinol Metab. 2006 Jul;91(7):2792-5. Epub 2006 May 2.

PMID:
16670163
38.

The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction.

Bacci S, Ludovico O, Prudente S, Zhang YY, Di Paola R, Mangiacotti D, Rauseo A, Nolan D, Duffy J, Fini G, Salvemini L, Amico C, Vigna C, Pellegrini F, Menzaghi C, Doria A, Trischitta V.

Diabetes. 2005 Oct;54(10):3021-5.

39.

Lack of evidence for interaction between APM1 and PPARgamma2 genes in modulating insulin sensitivity in nondiabetic Caucasians from Italy.

Menzaghi C, Ercolino T, Salvemini L, Coco A, Fini G, Di Paola R, Doria A, Trischitta V.

J Intern Med. 2005 Mar;257(3):315-7. No abstract available.

40.

A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians.

Ma X, Bacci S, Mlynarski W, Gottardo L, Soccio T, Menzaghi C, Iori E, Lager RA, Shroff AR, Gervino EV, Nesto RW, Johnstone MT, Abumrad NA, Avogaro A, Trischitta V, Doria A.

Hum Mol Genet. 2004 Oct 1;13(19):2197-205. Epub 2004 Jul 28. Erratum in: Hum Mol Genet. 2005 Dec 15;14(24):3973.

PMID:
15282206
41.

The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients.

Bacci S, Menzaghi C, Ercolino T, Ma X, Rauseo A, Salvemini L, Vigna C, Fanelli R, Di Mario U, Doria A, Trischitta V.

Diabetes Care. 2004 Aug;27(8):2015-20.

PMID:
15277433
42.

Multigenic control of serum adiponectin levels: evidence for a role of the APM1 gene and a locus on 14q13.

Menzaghi C, Ercolino T, Salvemini L, Coco A, Kim SH, Fini G, Doria A, Trischitta V.

Physiol Genomics. 2004 Oct 4;19(2):170-4. Epub 2004 Jul 13.

PMID:
15252189
43.
44.

Insulin modulates PC-1 processing and recruitment in cultured human cells.

Menzaghi C, Di Paola R, Baj G, Funaro A, Arnulfo A, Ercolino T, Surico N, Malavasi F, Trischitta V.

Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E514-20. Epub 2002 Nov 19.

45.

A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome.

Menzaghi C, Ercolino T, Di Paola R, Berg AH, Warram JH, Scherer PE, Trischitta V, Doria A.

Diabetes. 2002 Jul;51(7):2306-12.

46.

Genetic variability in insulin action inhibitor Ikkbeta (IKBKB) does not play a major role in the development of type 2 diabetes.

Menzaghi C, Plengvidhya N, Ma X, Warram JH, Shoelson SE, Doria A.

J Clin Endocrinol Metab. 2002 Apr;87(4):1894-7.

PMID:
11932336
47.

T426I a new mutation in the thyroid hormone receptor beta gene in a sporadic patient with resistance to thyroid hormone and dysmorphism. Mutations in brief no. 192. Online.

Menzaghi C, Di Paola R, Corrias A, Einaudi S, Trischitta V, De Sanctis C, De Filippis V.

Hum Mutat. 1998;12(4):289.

PMID:
10660344
48.

Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor.

Di Cerbo A, Di Paola R, Menzaghi C, De Filippis V, Tahara K, Corda D, Kohn LD.

J Clin Endocrinol Metab. 1999 Sep;84(9):3283-92.

PMID:
10487700
49.

Association between an R338L mutation in the thyroid hormone receptor-beta gene and thyrotoxic features in two unrelated kindreds with resistance to thyroid hormone.

Menzaghi C, Balsamo A, Di Paola R, Gallone G, Rossi C, Tassi V, Fonzo D, De Filippis V.

Thyroid. 1999 Jan;9(1):1-6.

PMID:
10037068
50.

Cyclooxygenase-dependent thyroid cell proliferation induced by immunoglobulins from patients with Graves' disease.

Di Paola R, Menzaghi C, De Filippis V, Corda D, Di Cerbo A.

J Clin Endocrinol Metab. 1997 Feb;82(2):670-3.

PMID:
9024274

Supplemental Content

Loading ...
Support Center